The US Food and Drug Administration (FDA) has approved idecabtagene vicleucel (ide-cel) (Abecma, Bristol-Myers Squibb/2seventy bio) for adults with relapsed or refractory multiple myeloma after two […]

SAN DIEGO — Fewer than half of the cancer drugs approved under the US Food and Drug Administration’s (FDA’s) accelerated approval pathway between 2013 and 2017 […]

Healthcare providers hold wide-ranging opinions about prescribing opioids for chronic cancer pain, and many are haunted by the conflicting factors driving their views, from legal concerns […]

TOPLINE: Being positive for Helicobacter pylori is associated with a higher risk for colorectal cancer (CRC) incidence and CRC mortality, new data show; however, a 2-week […]

A San Antonio oncology practice and diagnostic reference laboratory have agreed to settle a federal lawsuit, which alleged the two entities had entered an unlawful kickback […]

Last year, oncologists dealt with the most severe cancer drug shortage to date. Over about 6 months in 2023, cancer centers across the United States struggled […]

TOPLINE: In stage N0-1 nasopharyngeal cancer, elective upper-neck irradiation provides outcomes on par with whole-neck irradiation and with significantly lower rates of long-term toxicity, according to […]

NEW YORK (Reuters) -Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said […]

TOPLINE: Using polygenic risk scores along with positive family histories and breast cancer-associated gene mutations improves risk stratification for breast cancer screening. METHODOLOGY: A polygenic risk […]